Biotech Values

[DewDiligence]

Partnership/licensing/acquisition factoids from MRK’s Cowen webcast:

In 2008, MRK investigated ~6,000 prospective drug-development partnerships, licenses, and acquisitions.

Of these, ~600 (10%) progressed to the stage of signing non-disclosure agreements.

Of these, 60 (1% of the original 6,000) resulted in a consummated business transaction.

In other words, 99% of the 6,000 prospective deals MRK investigated during 2008 were for naught. Presumably, MRK is not materially different from other Big Pharma in this regard.